View Older Stories View More Recent Stories

Jun 13, 2016 05:00PM Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
Jun 9, 2016 05:00PM Gilead Sciences to Present at the Jefferies 2016 Healthcare Conference on Friday, June 10
Jun 7, 2016 05:00PM Gilead Sciences to Present at the Goldman Sachs 37th Annual Global Healthcare Conference on Wednesday, June 8
May 27, 2016 07:30AM Gilead's (GILD) Epclusa Receives Positive CHMP Opinion for Treatment of All Genotypes of Chronic HCV
May 27, 2016 07:25AM European CHMP Adopts Positive Opinion for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
May 24, 2016 04:31PM Gilead Sciences (GILD) Names Kevin Young CBE as COO
May 24, 2016 04:30PM Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy
May 20, 2016 05:00PM Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23
May 9, 2016 05:00PM Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10
Apr 29, 2016 08:24AM Gilead (GILD) Announces CHMP Adopts Positive Opinion for TAF-Based Single Tablet Regimen Odefsey for Treatment of HIV
Apr 29, 2016 08:21AM European CHMP Adopts Positive Opinion for Gilead’s TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for Treatment of HIV
Apr 28, 2016 04:02PM Gilead Sciences Announces Second Quarter 2016 Dividend
Apr 25, 2016 07:11AM Gilead's (GILD) Descovy Granted EMA Marketing Authorization for Two Dosages
Apr 25, 2016 07:10AM European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV
Apr 21, 2016 05:00PM Gilead Sciences to Release First Quarter 2016 Financial Results on Thursday, April 28, 2016
Apr 18, 2016 06:29AM Gilead Sciences (GILD) Presents Data for Several HCV Inhibitor Phase 2, 3s; Includes Potential New Harvoni Indication
Apr 18, 2016 06:28AM Gilead Sciences (GILD) Announces Presentation of New Data for NASH, PSC Treatments
Apr 16, 2016 07:30AM Gilead Announces Multiple Scientific Presentations Demonstrating Broad Utility of Sofosbuvir-Based Hepatitis C Therapies
Apr 16, 2016 06:30AM Gilead Presents New Data Highlighting Progress in Liver Fibrosis
Apr 15, 2016 06:22AM Gilead Sciences (GILD) Offers Results from Two TAF Phase 3s; Both Studies Met Primary Endpoints
Apr 15, 2016 04:30AM Gilead Announces Full 48-Week Results From Two Phase 3 Studies Evaluating Tenofovir Alafenamide (TAF) for Patients With Chronic Hepatitis B Infection
Apr 4, 2016 02:57PM Gilead Sciences (GILD) Announces FDA Approval of Descovy as TAF-Based HIV Therapy
Apr 4, 2016 02:57PM U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy
Mar 31, 2016 06:54AM Gilead Sciences (GILD) Announces Submission of NDA for TAF as HBV Treatment to Japan's PMDA
Mar 31, 2016 02:02AM Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection
Mar 10, 2016 05:00PM Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 15
Mar 4, 2016 06:00PM Gilead Sciences Announces Settlement Method for 1.625% Convertible Senior Notes Due 2016
Mar 4, 2016 04:00PM Gilead Sciences to Present at the Cowen & Company 36th Annual Health Care Conference on Monday, March 7
Mar 1, 2016 02:07PM Gilead Sciences (GILD) Announces FDA Approval of Odefsey as HIV-1 Treatment in Certain Patients
Mar 1, 2016 02:06PM U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Feb 26, 2016 07:52AM European CHMP Adopts Positive Opinion for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine/Tenofovir Alafenamide) for the Treatment of HIV
Feb 25, 2016 10:41AM Gilead (GILD) Announces EMA Validates MAA for Tenofovir Alafenamide in Treatment of Hepatitis B
Feb 25, 2016 10:37AM European Medicines Agency Validates Gilead’s Marketing Application for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Feb 24, 2016 12:17PM Gilead Sciences (GILD) Issues Preclinical Data from Investigational TLR7 in HIV Eradication; SIV DNA Reduction Noted
Feb 24, 2016 12:09PM Gilead Announces Data From New Preclinical Study Evaluating an Investigational TLR7 Agonist in SIV-Infected Monkeys
Feb 23, 2016 05:00PM Gilead Sciences to Present at the RBC Capital Markets 2016 Healthcare Conference on Wednesday, February 24
Feb 23, 2016 01:04PM Gilead Sciences (GILD) Reports Results From Study to Evaluate Switching to F/TAF-Based Regimens from Truvada (F/TDF)-Based Regimens
Feb 23, 2016 12:10PM Gilead Announces Results From First Study to Evaluate Switching to F/TAF-Based Regimens from Truvada® (F/TDF)-Based Regimens
Feb 22, 2016 08:31AM Gilead Launches New Grants Program to Support HIV Cure
Feb 16, 2016 08:31AM Gilead Sciences (GILD) Announces FDA Approval of Two Additional Harvoni Indications
Feb 16, 2016 08:30AM U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
Feb 8, 2016 05:00PM Gilead Sciences to Participate in Two Upcoming Investor Conferences
Feb 2, 2016 04:01PM Gilead Sciences Announces Declaration of Q1 Cash Dividend and Increases to Shareholder Return Programs
Feb 1, 2016 05:00PM Gilead Announces Promotion of Katie Watson to Executive Vice President, Human Resources
Feb 1, 2016 09:09AM Gilead Sciences (GILD) Announces EMA Validates Type II Variation Application for Truvada
Feb 1, 2016 09:02AM European Medicines Agency Validates Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Jan 29, 2016 08:17AM Gilead Sciences (GILD) Names John Milligan CEO
Jan 29, 2016 08:00AM Gilead’s John C. Martin, PhD to Assume Role of Executive Chairman of the Board; John F. Milligan, PhD to Be Appointed Chief Executive Officer and Director
Jan 26, 2016 05:00PM Gilead Sciences to Release Fourth Quarter and Full Year 2015 Financial Results on Tuesday, February 2, 2016
Jan 12, 2016 08:32AM Gilead Sciences (GILD) Announces Sumission of NDA for TAF to U.S. FDA
View More Recent Stories View Older Stories